Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21324922 | 0.80 | CHRNB4 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL21324932 | 0.80 | CHRNB4 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL21325080 | 0.73 | CA1 (0.35) | — | |
| SCHEMBL20393748 | 0.68 | TRPV1 (0.35) | KCNN4 | |
| SCHEMBL20351583 | 0.68 | SCN9A (0.34) | — | |
| SCHEMBL20201668 | 0.67 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20201654 | 0.67 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL22548331 | 0.67 | HTR2C (0.36) | — | |
| SCHEMBL29303917 | 0.66 | LTA4H (0.63) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL10326838 | 0.66 | LTA4H (0.63) | CHRNB4CHRNA3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CHRNB4 4783/4885CHRNA3 4767/4885CHRNB2 4711/4885 |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | CHRNB4 4783/4885CHRNA3 4767/4885CHRNB2 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.